CL2018003821A1 - Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. - Google Patents

Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.

Info

Publication number
CL2018003821A1
CL2018003821A1 CL2018003821A CL2018003821A CL2018003821A1 CL 2018003821 A1 CL2018003821 A1 CL 2018003821A1 CL 2018003821 A CL2018003821 A CL 2018003821A CL 2018003821 A CL2018003821 A CL 2018003821A CL 2018003821 A1 CL2018003821 A1 CL 2018003821A1
Authority
CL
Chile
Prior art keywords
triazolo
pyridinyl
compounds
compounds substituted
indole compounds
Prior art date
Application number
CL2018003821A
Other languages
English (en)
Inventor
Shoshana L Posy
Alaric J Dyckman
John E Macor
Ramesh Kumar Sistla
Dharmpal S Dodd
Tasir Shamsul Haque
Louis J Lombardo
Christopher P Mussari
Laxman Pasunoori
Kumar Sreekantha Ratna
Trevor C Sherwood
Subramaya Hegde
Anupama Ramachandra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2018003821A1 publication Critical patent/CL2018003821A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA (1) O UNA SAL DEL MISMO, EN DONDE R1, R2, R3, R4, R5, M, N Y P SE DEFINEN EN LA PRESENTE. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR TALES COMPUESTOS COMO INHIBIDORES DE LA SEÑALIZACIÓN A TRAVÉS DEL RECEPTOR TIPO TOLL 7, 8 O 9, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS. ESTOS COMPUESTOS SON ÚTILES PARA TRATAR ENFERMEDADES INFLAMATORIAS Y AUTOINMUNITARIAS.
CL2018003821A 2016-06-29 2018-12-27 Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. CL2018003821A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611022328 2016-06-29
US15/635,055 US10071079B2 (en) 2016-06-29 2017-06-27 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Publications (1)

Publication Number Publication Date
CL2018003821A1 true CL2018003821A1 (es) 2019-04-22

Family

ID=60805851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003821A CL2018003821A1 (es) 2016-06-29 2018-12-27 Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.

Country Status (31)

Country Link
US (8) US10071079B2 (es)
EP (1) EP3478682B1 (es)
JP (1) JP6995067B6 (es)
KR (1) KR102473482B1 (es)
CN (1) CN109641895B (es)
AR (1) AR108905A1 (es)
AU (1) AU2017287902B2 (es)
BR (1) BR112018077119A2 (es)
CA (1) CA3029620A1 (es)
CL (1) CL2018003821A1 (es)
CO (1) CO2019000686A2 (es)
CY (1) CY1124514T1 (es)
DK (1) DK3478682T3 (es)
EA (1) EA037530B1 (es)
ES (1) ES2886964T3 (es)
HR (1) HRP20211261T8 (es)
HU (1) HUE056091T2 (es)
IL (1) IL263961B (es)
LT (1) LT3478682T (es)
MX (1) MX2018015422A (es)
MY (1) MY196474A (es)
PE (1) PE20190324A1 (es)
PL (1) PL3478682T3 (es)
PT (1) PT3478682T (es)
RS (1) RS62292B1 (es)
SG (1) SG11201811590RA (es)
SI (1) SI3478682T1 (es)
TW (1) TWI636053B (es)
UY (1) UY37310A (es)
WO (1) WO2018005586A1 (es)
ZA (1) ZA201900571B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3490983B1 (en) 2016-07-30 2021-02-17 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
MA46188A (fr) 2016-09-09 2019-07-17 Bristol Myers Squibb Co Composés indole substitués par pyridyle
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
JP7266576B2 (ja) * 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
CN111448190B (zh) * 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
CN111527080B (zh) * 2017-12-15 2023-09-22 百时美施贵宝公司 取代的吲哚醚化合物
CA3085590A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
AU2018392316B2 (en) 2017-12-19 2022-05-12 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
ES2965182T3 (es) 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
MX2020005513A (es) * 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
CA3093888A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
WO2020020800A1 (en) 2018-07-23 2020-01-30 F. Hoffmann-La Roche Ag Novel piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP7233809B2 (ja) 2018-09-04 2023-03-07 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのベンゾチアゾール化合物
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
JP2022505827A (ja) * 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール二量体の化合物
WO2020086503A1 (en) * 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
IL282535B2 (en) 2018-10-31 2024-05-01 Gilead Sciences Inc Transformed 6-azabanzimidazole compounds as HPK1 inhibitors
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137517A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
CN113574063A (zh) 2019-03-07 2021-10-29 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
JP2022532568A (ja) 2019-05-07 2022-07-15 ブリストル－マイヤーズ スクイブ カンパニー プロドラッグ化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN110146631B (zh) * 2019-06-25 2021-11-12 山西康宝生物制品股份有限公司 一种药用材料中聚乙二醇单甲醚残留量的检测方法
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
PE20221111A1 (es) 2019-09-30 2022-07-11 Gilead Sciences Inc Vacunas para vhb y metodos de tratamiento de vhb
EP4069729A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20230023717A (ko) 2020-06-11 2023-02-17 브리스톨-마이어스 스큅 컴퍼니 피부 홍반성 루푸스를 치료하기 위한 프레드니솔론 또는 히드록시클로로퀸과 조합된 tlr7 억제제
EP4168049A1 (en) 2020-06-22 2023-04-26 Bristol-Myers Squibb Company Treating rheumatoid arthritis
TW202214632A (zh) * 2020-07-27 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用
JP2023550793A (ja) 2020-11-26 2023-12-05 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合三環式化合物、その調製方法及びその医薬的応用
JP2024513945A (ja) 2021-04-16 2024-03-27 ギリアード サイエンシーズ， インコーポレイテッド チオノピロール化合物
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
CN113416188B (zh) * 2021-05-31 2022-12-13 河南偶联生物科技有限公司 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2024015825A1 (en) 2022-07-13 2024-01-18 Bristol-Myers Squibb Company Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532479A (ja) 1998-12-18 2002-10-02 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼインヒビター
AU2004257149A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
WO2006113458A1 (en) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
US20090099179A1 (en) 2006-04-04 2009-04-16 Myriad Genetics, Incorporated Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US7977352B2 (en) 2006-12-01 2011-07-12 Galapagos Nv Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
RU2011153723A (ru) 2009-06-10 2013-07-20 Суновион Фармасьютикалз Инк. Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011009015A1 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US9241991B2 (en) 2010-10-21 2016-01-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritus and related skin conditions
AU2012205490B2 (en) 2011-01-12 2017-02-02 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
JP5985509B2 (ja) 2011-01-12 2016-09-06 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様受容体調節薬としての置換ベンゾアゼピン
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
RU2606114C2 (ru) 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы
US9181214B2 (en) 2011-06-09 2015-11-10 Rhizen Pharmaceuticals Sa Bicyclic compounds as modulators of GPR-119
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
AU2013261267B2 (en) 2012-05-18 2017-06-29 Sumitomo Pharma Co., Ltd. Carboxylic acid compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
PT3057964T (pt) 2013-10-14 2020-02-25 Eisai R&D Man Co Ltd Compostos de quinolina seletivamente substituídos
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US10106574B2 (en) 2015-08-13 2018-10-23 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
TN2018000452A1 (en) 2016-06-29 2020-06-15 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
MX2018016387A (es) 2016-06-29 2019-09-09 Kezar Life Sciences Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
EP3490983B1 (en) 2016-07-30 2021-02-17 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
MA46188A (fr) 2016-09-09 2019-07-17 Bristol Myers Squibb Co Composés indole substitués par pyridyle
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
CN111527080B (zh) 2017-12-15 2023-09-22 百时美施贵宝公司 取代的吲哚醚化合物
EP3728252B1 (en) 2017-12-18 2023-08-09 Bristol-Myers Squibb Company 4-azaindole compounds
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
AU2018392316B2 (en) 2017-12-19 2022-05-12 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
CA3085590A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
ES2965182T3 (es) 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
JP2022505827A (ja) 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール二量体の化合物
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds

Also Published As

Publication number Publication date
LT3478682T (lt) 2021-09-27
RS62292B1 (sr) 2021-09-30
US11672780B2 (en) 2023-06-13
AR108905A1 (es) 2018-10-10
JP2019523241A (ja) 2019-08-22
AU2017287902A1 (en) 2019-02-14
USRE49880E1 (en) 2024-03-26
USRE49893E1 (en) 2024-04-02
US20180000790A1 (en) 2018-01-04
PL3478682T3 (pl) 2021-12-13
MX2018015422A (es) 2019-04-22
US10912766B2 (en) 2021-02-09
HRP20211261T8 (hr) 2022-01-21
ES2886964T3 (es) 2021-12-21
SI3478682T1 (sl) 2021-10-29
ZA201900571B (en) 2020-10-28
JP6995067B2 (ja) 2022-01-14
SG11201811590RA (en) 2019-01-30
US10478424B2 (en) 2019-11-19
PT3478682T (pt) 2021-09-15
US20210085651A1 (en) 2021-03-25
CN109641895B (zh) 2021-09-03
CN109641895A (zh) 2019-04-16
IL263961B (en) 2021-01-31
US20180325874A1 (en) 2018-11-15
TW201805285A (zh) 2018-02-16
UY37310A (es) 2018-01-02
EP3478682A1 (en) 2019-05-08
BR112018077119A2 (pt) 2019-04-02
USRE49931E1 (en) 2024-04-23
TWI636053B (zh) 2018-09-21
EA037530B1 (ru) 2021-04-08
KR102473482B1 (ko) 2022-12-01
HRP20211261T1 (hr) 2021-11-26
CY1124514T1 (el) 2022-07-22
IL263961A (en) 2019-01-31
US10071079B2 (en) 2018-09-11
US20200038374A1 (en) 2020-02-06
MY196474A (en) 2023-04-13
CA3029620A1 (en) 2018-01-04
JP6995067B6 (ja) 2023-12-14
KR20190022735A (ko) 2019-03-06
EA201990048A1 (ru) 2019-05-31
DK3478682T3 (da) 2021-09-13
WO2018005586A1 (en) 2018-01-04
AU2017287902B2 (en) 2021-09-16
PE20190324A1 (es) 2019-03-05
EP3478682B1 (en) 2021-07-21
CO2019000686A2 (es) 2019-02-19
HUE056091T2 (hu) 2022-01-28
US20230255941A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
CL2018003821A1 (es) Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.
CO2019011584A2 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos
CL2020001546A1 (es) Compuestos de 4-azaindol.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA202091474A1 (ru) Замещенные индольные соединения, применимые в качестве ингибиторов tlr
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201590228A1 (ru) Антагонисты 5-ht3 рецептора
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
EA201990400A1 (ru) Соединения и композиции и их применение
EA201700042A1 (ru) Соединения имидазопиридазина
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA202090414A1 (ru) Соединения и их применение
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6